NAD+ Injection Routes UAE: SC vs IM vs IV vs Intranasal — What the Research Actually Shows

Why Route Matters for NAD+

NAD+ (nicotinamide adenine dinucleotide) is one of the most studied longevity research compounds, but it is also one of the most route-sensitive. Unlike GLP-1s or BPC-157 where SC is the obvious default, NAD+ behaves differently in every compartment — and the dosing math, pain profile, and onset all shift dramatically by route.

The molecule is large (~663 Da), polar, and unstable in oral form (Trammell 2016 confirmed near-zero oral bioavailability of intact NAD+; the body cleaves it to nicotinamide before absorption). So injection is the route researchers care about — and the four candidate routes are SC, IM, IV, and intranasal.

Route 1 — Subcutaneous (SC)

What the data shows

SC NAD+ at 100–250 mg per session with a slow 10–15 minute push produces plasma NAD+ concentrations approaching 60–80% of an equivalent IV dose (Conlon 2021 pharmacokinetic series). The slow injection rate is critical — fast SC push generates the same burning and flushing as IV bolus.

Practical notes

• Split the dose. Researchers commonly split 250 mg across two abdominal sites to halve the concentration burn.
• Warm vial to body temp first. Cold NAD+ stings more.
• Use 27–29G insulin needles. The viscosity is fine through a small bore if the push is slow.

Route 2 — Intramuscular (IM)

IM NAD+ is sometimes used when SC sites are tender or atrophic. Bioavailability is similar to SC (Yoshino 2021), but the pain profile is worse — IM NAD+ stings sharply for the first 60–90 seconds and can leave a deep ache for hours.

Most research groups have moved away from IM as a default because the tolerability disadvantage is not offset by faster onset. The exception: athletes already comfortable with IM injection technique who prefer thigh or deltoid sites.

Route 3 — Intravenous (IV)

IV NAD+ is the clinical gold standard and the route most published longevity studies use (Yoshino 2021; Martens 2018 used the NMN precursor IV in their phase 1). Doses run 500–1000 mg per session, infused over 2–4 hours in a clinic setting.

Why so slow?

Fast IV NAD+ push triggers a well-documented reaction cascade: facial flushing, chest tightness, abdominal cramping, nausea. Slowing the drip to 100–250 mg/hr eliminates most of this. Conlon 2021 documented that drip rate, not total dose, predicts side-effect intensity.

Route 4 — Intranasal

Intranasal delivery has theoretical appeal for brain-focused research because of the nasal-to-brain transit pathway that bypasses the blood-brain barrier. Grant 2019 demonstrated intranasal NAD+ reaches brain tissue in rodent models within minutes.

However, the systemic bioavailability is poor — typically under 10% of an equivalent SC dose. For systemic longevity research (mitochondrial function, NAD/NADH ratio normalisation), intranasal is the wrong tool. For cognitive or neuroprotective research questions, it may have a niche but the human data is still thin.

Route Comparison Table

UAE Research Context

For UAE-based researchers working in 45°C summer conditions, two route-specific considerations matter:

• NAD+ stability at temperature. Reconstituted NAD+ should be refrigerated and used within 5–7 days. Heat exposure during transport accelerates degradation — see our UAE cold-chain shipping guide for handling protocols.
• IV access in Dubai/Abu Dhabi. Clinical NAD+ IV is available at several wellness clinics but pricing is AED 1,500–3,500 per session. SC self-administration with researcher-grade NAD+ runs a fraction of that per mg — see our reconstitution calculator.

Practical Decision Framework

1. Is the research question systemic (longevity, metabolic, mitochondrial)? → SC slow push is the default.
2. Is maximum plasma concentration required? → IV in a clinic setting.
3. Is the question CNS-focused (cognition, neuroprotection)? → Consider intranasal as adjunct, not replacement.
4. Are SC sites unavailable? → IM with acceptance of sharper pain.